These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12520083)

  • 1. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement.
    Karamanolakis D; Bogdanos J; Sourla A; Milathianakis C; Tsintavis A; Lembessis P; Tenta R; Tiblalexi D; Koutsilieris M
    Mol Med; 2002 Nov; 8(11):667-75. PubMed ID: 12520083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of detection of bone-marrow micrometastasis in prostate carcinoma patients by CK18/PSA immunocytochemistry and PSA RT-PCR.
    Albers P; Ko Y; Wardelmann E; Schmidt D; Adam M; Vetter H; Müller SC
    Anticancer Res; 2000; 20(3B):2107-11. PubMed ID: 10928161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
    Gomella LG; Raj GV; Moreno JG
    J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in bone-targeted therapies of metastatic prostate cancer.
    Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
    Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
    Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
    J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
    Okubo Y; Ito T
    Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
    Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
    J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
    J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
    Kufer P; Zippelius A; Lutterbüse R; Mecklenburg I; Enzmann T; Montag A; Weckermann D; Passlick B; Prang N; Reichardt P; Dugas M; Köllermann MW; Pantel K; Riethmüller G
    Cancer Res; 2002 Jan; 62(1):251-61. PubMed ID: 11782385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
    Hara N; Kasahara T; Kawasaki T; Bilim V; Obara K; Takahashi K; Tomita Y
    Clin Cancer Res; 2002 Jun; 8(6):1794-9. PubMed ID: 12060619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases.
    Mimori K; Fukagawa T; Kosaka Y; Ishikawa K; Iwatsuki M; Yokobori T; Hirasaki S; Takatsuno Y; Sakashita H; Ishii H; Sasako M; Mori M
    Ann Surg Oncol; 2008 Oct; 15(10):2934-42. PubMed ID: 18661187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer.
    Fujita Y; Terashima M; Hoshino Y; Ohtani S; Kashimura S; Kanzaki N; Osuka F; Kogure M; Gotoh M
    Gastric Cancer; 2006; 9(4):308-14. PubMed ID: 17235634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
    Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.